New combo therapy aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07187674
First seen Oct 31, 2025 · Last updated Jun 14, 2026 · Updated 34 times
Summary
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted drug (olaparib) and chemotherapy (paclitaxel) can eliminate cancer before surgery in 20 women with early high-risk triple negative breast cancer that has a specific genetic marker (HRD positive). Participants receive six 3-week cycles of treatment, then undergo standard breast cancer surgery. The main goal is to see if no cancer remains in the breast or lymph nodes after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.